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The present work describes new supramolecular aggregates obtained by co-assembling two
diﬀerent amphiphilic molecules, one containing the bioactive bombesin peptide (BN), or a
scramble sequence, and the other, the DOTA chelating agent, (C18)2DOTA, capable of forming
stable complexes with the radioactive 111In(III) isotope. The peptide in the amphiphilic monomer
is spaced by the lipophilic moiety through ethoxylic spacers of diﬀerent length: a shorter spacer
with ﬁve units of dioxoethylene moieties in (C18)2L5-peptide, or a longer spacer consisting of a
Peg3000 residue in (C18)2Peg3000-peptide. Structural characterization by SANS and DLS
techniques indicates that, independently from the presence of the peptide containing monomer in
the ﬁnal composition, the predominant aggregates are liposomes of similar shape and size with a
hydrodynamic radius Rh around 200 nm and bilayer thickness, d, of 4 nm. In vitro data show
speciﬁc binding of the 111In-(C18)2DOTA/(C18)2L5-[7-14]BN 90 : 10 liposomes in receptor
expressing cells. However, the presence of the Peg3000 unit on the external liposomal surface,
could hide the peptide and prevent the receptor binding. In vivo experiments using
111In-(C18)2DOTA/(C18)2L5-[7-14]BN show the expected biological behavior of aggregates
of such size and molecular composition, moreover there is an increase in concentration
of the GRPR targeting aggregate in the tumors compared to control at the 48 h time point
evaluated (2.4% ID/g versus 1.6% ID/g).
1. Introduction
Multimodal supramolecular compounds that combine
imaging and therapeutic capabilities are the focus of intensive
research for applications in the growing ﬁeld of nano-
medicine.1,2 They oﬀer the prospect to increase diagnostic
accuracy and therapeutic eﬀectiveness, while minimizing side
eﬀects from treatment. Nanoparticles with a micellar or
liposomal structure obtained by assembling amphiphilic
compounds are promising candidates for such multifunctional
therapeutic platforms, since these materials are conveniently
synthesized, variably functionalized, and can be assembled to a
range of sizes and compositions. They have high drug-loading
capacity, biodegradability, prolonged circulation times, slow
plasma clearance and controllable drug-release proﬁles. The
hydrophobic core of micelles and the inner cavity of liposomes
are carrier compartments able to accommodate large amounts
of drug, while the shell, consisting of a brush-like protecting
corona, stabilizes them in aqueous solutions.3,4 Moreover
micelles and liposomes can be functionalized on their external
surface by introducing reporter molecules such as peptides or
antibodies to achieve speciﬁc and selective delivery to target
cells,5,6 and they can also be modiﬁed with a ﬂuorescent,
paramagnetic or radioactive probe for their visualization and
for diagnostic purposes.7
An eﬀective way to prepare nanoparticles with a micellar or
liposomal structure modiﬁed with a reporter compound on
their surface and with a paramagnetic or radioactive probe is
the mixed assembly of diﬀerent monomers. We have recently
developed micelles and liposomes acting as target selective
MRI contrast agents,8–11 or as target selective drug delivery
systems.12,13 They have been obtained by co-assembling two
diﬀerent amphiphilic molecules, one containing a bioactive
peptide and the other a chelating moiety capable of forming
stable complexes with the paramagnetic Gd(III) ion or with the
radioactive 111In(III) isotope. Following this strategy we have
now developed new thera-diagnostic supramolecular aggregates
that can potentially act as target selective drug delivery systems
and imaging probes, thus coupling together therapeutic and
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diagnostic eﬀectiveness. These new aggregates have been
designed to target the members of the bombesin receptor
family, which consists of four receptor subtypes including the
neuromedin B receptor (BB1), the gastrin-releasing peptide
receptor (GRPR, BB2), the orphan receptor subtype (BB3),
and the amphibian receptor (BB4).14–17
The bombesin receptor subtype 2 (GRPR) has been
found overexpressed by tumor cell lines of several human
tumors (ovarian cancers, breast cancers and prostate
cancer)18–20 and thus it is indicated as a potential target for
tumor diagnosis and selective therapy. The fourteen-residue
bombesin peptide (BN), its eight-residue C-terminal peptide
sequence ([7-14]BN), or some other bombesin analogue could
act as antagonists and be used to target these receptors. Many
studies have demonstrated that bombesin fragment [7-14]BN
modiﬁed on the N-terminus with radiometal complexes for
nuclear medicine applications preserves its aﬃnity for
these receptors.21 Rogers and co-workers22,23 evaluated the
behavior of BN analogues containing aliphatic or amino
acidic linkers placed between the BN peptide and the
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)
chelator. Results conﬁrmed the target cell uptake with IC50
values in the nanomolar range in in vitro experiments and in
in vivo studies.
In the present study, we report on new mixed supra-
molecular aggregates obtained by mixing the two amphiphilic
monomers shown in Fig. 1. The more abundant monomer,
used to drive the aggregation process, is the anionic surfactant
(C18)2DOTA, (monomer A in Fig. 1); it contains two C18
alkyl chains that allow the formation of supramolecular
aggregates in water solution, a lysine residue acting as spacer,
and the DOTA chelator. This cyclic chelating agent is able to
coordinate radioactive metal ions such as 111In(III) or 67/68Ga(III),
allowing the in vivo biodistribution of the aggregates to be
followed by using nuclear medicine techniques.24 The other,
bioactive, amphiphilic monomer contains the same hydrophobic
moiety with two C18 alkyl chains, and the bombesin analogue
[7-14]BN. The peptide is spaced by the lipophilic moiety
through ethoxylic spacers of diﬀerent length. Two diﬀerent
spacers are used: a shorter spacer with ﬁve units of dioxoethylene
moieties (monomer B, in Fig. 1) or a longer spacer consisting
of a Peg3000 residue (monomer C in Fig. 1). The spacer
performs several important tasks: it increases the peptide
hydrophilicity; it distances the bioactive peptide from the
surface of the supramolecular aggregate, thus giving a better
peptide exposition and reducing potential hindrance to peptide
binding activity; moreover it prevents the aggregates from
being cleared through the reticulo-endothelial system (RES).25
The in vitro and in vivo target selectivities of aggregates
exposing the [7-14]BN peptide were compared with similar
aggregates derivatized with a scrambled peptide, scrBN. The
internalization rate of the 111In labeled aggregates into PC-3
(human prostate cancer cell line) cells was studied and the
pharmacokinetics of the more promising aggregate was
evaluated in PC-3 tumor bearing nude mice.
2. Results and discussion
2.1 Monomers synthesis and aggregates preparation
The peptide conjugate DOTA-bAla-[7-14]BN, and the
amphiphilic monomers (C18)2L5-[7-14]BN and (C18)2Peg3000-
[7-14]BN were synthesized by Fmoc/tBu chemistry according
to standard solid phase peptide synthesis protocols, using
Rink-amide MBHA resin as polymeric support.26 The corres-
ponding scrambled peptide compounds retaining the bombesin
[7-14] amino acid residue composition, but with a reordered
sequence, were prepared using similar procedures. As already
Fig. 1 Schematic representation of amphiphilic monomers: (A) (C18)2DOTA; (B) (C18)2L5-[7-14]BN or (C18)2L5-scrBN(Sc);
(C) (C18)2Peg3000-[7-14]BN or (C18)2Peg3000-scrBN.
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experienced with similar compounds the introduction of the
Peg moiety or oxoethylene linkers was eﬃciently obtained by
using the Fmoc-protected starting reagents (Fmoc-NH-
Peg3000-COOH and ﬁve Fmoc-AdOO-OH, respectively),
using a two-fold molar excess in the solid-phase synthesis
protocols and PyBop/HOBt as activators. Also the hydro-
phobic N,N-dioctadecylsuccinamic acid was eﬃciently bound
in solid-phase in a DMF–DCM mixture. All the peptide
conjugates were collected in good yields after HPLC-RP
chromatography puriﬁcation. Analytical liquid chromatography
mass spectrometry (LC-MS) data conﬁrmed the compound
identities and their high purity. (C18)2DOTA anionic surfactant
was crystallized by adding water drop-wise to the TFA
cleavage solution and used without further puriﬁcation. The
identity of the product was conﬁrmed by ESI MS and by
NMR spectroscopy (1H and 13C). Pure aggregates of
(C18)2DOTA monomer, and mixed supramolecular aggregates
containing the (C18)2DOTA monomer and (C18)2DOTA/
(C18)2L5-[7-14]BN or (C18)2DOTA/(C18)2Peg3000-[7-14]BN
(or the aggregates containing the corresponding scrambled
sequences) were prepared in 90 : 10 molar ratio in phosphate
buﬀer at pH 7.4 following well known procedures.
2.2 Structural characterization
Fig. 2 shows the scattering cross sections collected for the
binary aqueous systems (C18)2DOTA and for the ternary
aqueous systems (C18)2DOTA/(C18)2L5-[7-14]BN. In Fig. 3,
examples of distribution functions obtained for hydrodynamical
radii by means of DLS measurements are reported for aqueous
systems (C18)2DOTA, (C18)2DOTA/(C18)2L5-[7-14]BN and
(C18)2DOTA/(C18)2Peg3000-[7-14]BN. Inspection of Fig. 2,
reveals that, for both systems, the scattering cross sections
dS/dO, at high q, show a power low (q2) typical of
bi-dimensional objects.
Actually, as also shown by DLS, this scattering behavior
can be ascribed to the presence of large liposomal aggregates,
whose Guinier regime falls almost completely in the very low
q value, undetectable with the SANS apparatus used. Thus,
the aggregates presented in our systems have been modeled as
a collection of randomly oriented planar sheets, for which the














where Dr is the scattering length density diﬀerence between the
scattering aggregates and the solvent, d is the plane thickness,
S is the total surface per unit volume and (dS/dO)incoh
represents the incoherent contribution to the scattering cross
section, mainly due to the presence of hydrogen nuclei. From a
ﬁtting of eqn (1) to the experimental data it is possible to
evaluate the thickness d of the liposome double layer for the
system analyzed. These values are collected in Table 1 together
with the values obtained from DLS experiments. Concerning
this latter technique, the distribution function obtained for the
hydrodynamic radii shows the presence of two diﬀusive modes
for (C18)2DOTA and (C18)2DOTA/(C18)2Peg3000-[7-14]BN
aqueous systems, whereas a single mode is present for the
(C18)2DOTA/(C18)2L5-[7-14]BN system. The experimental
self-diﬀusion coeﬃcients D, obtained through the regularized
inverse Laplace transformation of the correlation functions,
are collected in Table 1. In the approximation of very diluted
solutions, the data can be directly related to the hydrodynamic
radii (see Table 1) of the aggregates, Rh, through the
Stokes–Einstein equation, which holds for non-interacting
hard spheres diﬀusing in a continuous medium. The sizes
obtained for the aggregates formed by the synthesized
molecules are consistent with the dimensions of micelles and
liposomes, that coexist for (C18)2DOTA and (C18)2DOTA/
(C18)2Peg3000-[7-14]BN aqueous systems, whereas for the
(C18)2DOTA/(C18)2L5-[7-14]BN system only large aggregates
(liposomes) are present. However, in contrast with DLS
results, the presence of micellar structures has not been
detected in the SANS cross sections proﬁle. It is worthy
Fig. 2 Scattering cross sections at 25 1C of (C18)2DOTA/D2O (’)
and (C18)2DOTA/(C18)2L5-[7-14]BN/D2O (K). For a better
visualization, data have been multiplied by a scaling factor as indicated.
Curves obtained through the ﬁtting of eqn (1) are also reported.
Fig. 3 Hydrodynamical radius distribution function obtained at
25 1C by means of DLS measurements for the following systems:
(C18)2DOTA/H2O (—), (C18)2DOTA/(C18)2L5-[7-14]BN/H2O (---)
and (C18)2DOTA/(C18)2Peg3000-[7-14]BN/H2O ().
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to note that this circumstance does not imply the absolute
absence of the smaller aggregates but can be ascribed to
the ratio of the two populations that indicates a very large
amount of liposomes, thus hiding the contribution of
smaller micelles to the cross sectional scattering. By inspection
of Table 1 it can be inferred that the thicknesses of the
bilayers are fairly constant, around 41 A˚, in the two analyzed
systems. The low relative amount of the (C18)2L5-[7-14]BN
compared to the (C18)2DOTA in the 10 : 90 mixed aggregates
does not have a strong inﬂuence on the thickness of the
double layers. Moreover the three supramolecular aggregates,
independent of the presence of the peptide containing
monomer in the ﬁnal composition, show similar shapes and
sizes with a hydrodynamic radius Rh around 200 nm.
A schematic view of the liposomal aggregates is reported
in Fig. 4.
As it concerns the micellar aggregates found, in low amount,
in (C18)2DOTA and (C18)2DOTA/(C18)2Peg3000-[7-14]BN
samples, we note that DLS measurements are not able to
provide the shape and the detailed dimensions of these objects.
However, a simple calculation on the synthesized molecules,
by assuming an all-trans conformation, provides a linear
length of B40–60 A˚, quite far from the hydrodynamical
radius found for the micellar structures, probably due to the
formation of elongated structures like rod-like or worm-like
micelles. Finally, SANS measurements carried out on mixed
aggregates containing the monomer in which [7-14]BN peptide
is replaced with the scrambled peptide sequence (scrBN),
as expected, do not show signiﬁcant structural modiﬁcations
(data not shown).
2.3 In vitro studies
Binding and internalization assays of 111In-DOTA-bAla-
[7-14]BN and 111In-DOTA-bAla-scrBN peptide conjugates were
performed on PC-3 cell lines at 37 1C, at diﬀerent time points
(0.5, 1.0, 2.0 and 4.0 h), in order to conﬁrm the eﬀective binding
capability of [7-14]BN and to evaluate if the peptide sequence
chosen as scrambled peptide (scrBN) is an adequate negative
control for the aggregate systems. Blocking studies performed
using a large excess of [Tyr4]-BN demonstrated that the uptake
was receptor mediated. As shown in Fig. 5A, when incubating
PC-3 cells with trace amounts of 111In-DOTA-bAla-[7-14]BN,
we found 8.98  0.49% of the total amount of labeled peptide
bound or was internalized at 4 h. This data is in agreement with
previous reports in the literature27 that show high aﬃnity (IC50
of 2.1  0.3 nM) binding of 111In-DOTA-bAla-[7-14]BN to
the GRP receptor and the fact that high levels of receptors are
present on the cell surface of PC-3 cells (Bmax in the 1  104 to
1  105 range).28 Moreover, there is strong evidence for active
internalization of the receptor–ligand complex28 in these cells.
Furthermore, the control scrambled peptide shows almost no
binding and internalization. Our results conﬁrm the high
speciﬁc binding and internalization of 111In-DOTA-bAla-[7-14]BN
peptide in PC-3 cells.
Receptor-mediated cellular uptake kinetics of mixed
aggregates ((C18)2DOTA/(C18)2L5-[7-14]BN and (C18)2DOTA/
(C18)2Peg3000-[7-14]BN) were evaluated in a similar fashion.
The corresponding mixed aggregates in which the BN peptide
was replaced by a scrambled sequence ((C18)2L5-scrBN or
(C18)2Peg3000-scrBN) and aggregates containing only
(C18)2DOTA were used as negative controls. Radiolabeling of
the aggregates was performed at 2  104 M concentration.
Trace amounts of 111InCl3 and up to 100 mCi were added to the
aggregate formulation after addition of an equal volume of 0.4 N
sodium acetate buﬀer. Conﬁrmation of incorporation of the
radioactive label into the aggregates was obtained by gel ﬁltration.
Speciﬁc preferential binding to PC-3 cells of mixed aggregates
containing the ﬁve units of AdOO (L5 spacer) between the BN
peptide sequence and the hydrophobic chains was observed
(10.3  0.82% at 4 h, Fig. 5B), compared to the same
aggregates in which the BN peptide was replaced by a
scrambled sequence (5.92  0.78% at 4 h) and to the
Fig. 4 Schematic view of pure and mixed liposomal aggregates. In all cases, independent of the presence of 10% in peptide monomer in the ﬁnal
composition, liposomes show a hydrodynamic radius, Rh, around 200 nm and bilayer, d, thickness of 4 nm.
Table 1 Liposomal bilayer thickness (d), translational diﬀusion
coeﬃcient (D) and hydrodynamical radius (Rh) obtained for the
systems investigated by means of SANS and DLS
Aqueous system d/A˚ D/cm2 s1 Rh/nm
(C18)2DOTA 41  2 (1.28  0.07)108 190  11
(5.0  0.4) 108 49  4
(C18)2DOTA/
(C18)2L5-[7-14]BN
41  6 (1.2  0.1) 108 200  20
(C18)2DOTA/
(C18)2Peg3000-[7-14]BN
n.ma (1.15  0.04) 108 211  7
(1.15  0.05) 107 21  2
a not measured.
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(C18)2DOTA aggregates (1.63  0.14% at 4 h). Moreover,
binding experiments of mixed aggregates (C18)2DOTA/
(C18)2L5[7-14]BN were also performed after pre-incubation
of cells with the [Tyr4]-BN blocking reagent. Surprisingly,
under these experimental conditions liposomes containing
(C18)2DOTA alone show higher binding, with levels
comparable to those obtained with the BN containing mixed
aggregates (data not shown). We speculated that the
hydrophobic residues on the N-terminus of the peptide
may be encapsulated in the liposome bilayer during incubation
with the cells. This hypothesis was conﬁrmed by ﬂuorescence
spectroscopy experiments in which a solution containing
(C18)2DOTA aggregates was incubated, under stirring by
vortex for 1 min, with a small amount of [Tyr4]-BN (1 mg).
100 ml of the ﬁnal solution were separated by gel ﬁltration.
The presence in the ﬁrst gel ﬁltration fractions of a peak at
350 nm, corresponding to the ﬂuorescence emission of the Trp
residue in [Tyr4]-BN, conﬁrms encapsulation of the [Tyr4]-BN
in the aggregates. These results indicate that the [Tyr4]-BN
peptide is unsuitable as receptor blocking reagent in the
experiments with aggregates. As shown in Fig. 5B, mixed
aggregates show progressively increasing cell associated
radioactivity over time (60 min vs. 240 min), regardless of
which peptide is contained on the surface. Conversely,
(C18)2DOTA containing aggregates show no change in the
levels of cell associated activity over time. This phenomenon
could be related to the presence of the oxoethylene moieties in
the L5 linker that, as previously reported for Pegylated
liposomes, favors accumulation of aggregates on tumor cells.
By using similar binding experiments, we investigated the
behavior of (C18)2DOTA/(C18)2Peg3000[7-14]BN. The cell
associated radioactivity, as shown in Fig. 5C, is lower
compared to the values found for the aggregates containing
the L5 spacer in the peptide monomer.
We also observed similar values of cell associated radio-
activity at all time points investigated for the two aggregates
containing either the receptor speciﬁc [7-14]BN or the
scrambled control peptides. For example, at 4 h we found
5.20  0.39% and 4.89  0.35%, respectively. Even if these
values are higher compared to the (C18)2DOTA aggregates
(1.63  0.14% at 4 h), there is no apparent speciﬁcity in
binding and internalization due to the bioactive peptide
sequence. The presence of the Peg3000 unit on the external
liposomal surface may mask the peptide and prevent receptor
binding. Moreover, the presence of Peg3000 increases non-
speciﬁc binding to tumor cells compared to the (C18)2DOTA
containing aggregates. These results indicate that aggregates
containing a spacer with only ﬁve residues of AdOO yield
higher accumulation and superior speciﬁc interaction with the
PC-3 cells compared to aggregates containing the longer
Peg3000 spacer. Therefore, the (C18)2DOTA/(C18)2L5[7-14]BN
mixed aggregate was chosen for experiments in an animal
model, using the corresponding aggregate containing the
scrBN peptide as a negative control.
Fig. 5 Binding assays on PC-3 cell lines overexpressing the GRP at
37 1C, at diﬀerent time points (0.5, 1.0, 2.0 and 4.0 h): (A) binding of
111In-DOTA-bAla-[7-14]BN in comparison with 111In-DOTA-bAla-
scrBN radiolabeled peptides; (B) binding of 111In-labeled aggregates
(C18)2DOTA/(C18)2L5-[7-14]BN (90 : 10) with respect to the corres-
ponding aggregates in which the BN peptide is replaced by the BN
scrambled peptide and to the (C18)2DOTA pure aggregate;
(C) binding of 111In-labeled aggregates (C18)2DOTA/(C18)2Peg3000-
[7-14]BN in comparison with (C18)2DOTA/(C18)2L5-[7-14]BN
aggregates and with the (C18)2DOTA aggregate.
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2.4 In vivo studies
The in vivo biological behavior of 111In-(C18)2DOTA/
(C18)2L5[7-14]BN and
111In-(C18)2DOTA/(C18)2L5[7-14]scrBN
aggregates were evaluated after intravenous injection into
GRPR positive tumor bearing mice (PC-3 xenografts). Fig. 6
shows the results of these experiments. Time activity curves of
blood radioactivity concentration (Fig. 6a) show fairly long
circulation times of the aggregates. This is expected and
desired as the intended application of these aggregates is drug
delivery that requires high blood concentration of drugs for
prolonged periods of time. The observed circulating half-lives
of 4–5 h are in agreement with published reports on similar
aggregates29 and are the equivalent of 2–3 day half lives in
humans.30 Biodistribution at 48 h (Fig. 6b) indicates that most
radioactivity is in the liver whereas lower levels are obtained in
the other organs. Among the other organs, tumors show
relatively high concentrations and the GRPR targeting
111In-(C18)2DOTA/(C18)2L5-[7-14]BN aggregates show higher
concentrations in the PC-3 tumors compared to the scrambled
peptide containing control aggregates. There is a slight
increase in concentration of the GRPR targeting aggregate
in the tumors compared to the control at the 48 h time point
evaluated (2.4% ID/g versus 1.6% ID/g). The 50% increase in
the receptor uptake with respect to the control is similar to the
value found for supramolecular aggregates derivatized with
CCK8 peptide, in which an average enrichment factor of 48%
was observed.13 This ﬁnding justiﬁes further evaluation of this
approach. It is noteworthy to point out that the overall
accumulation of a potential drug carried by the aggregates
to the target tumor is not only dependent on concentration of
the aggregate in the tumor at the single time point but is also
dependent on aggregate concentration as a function of time.
Thus the integral of drug concentration in the tumor versus
time is likely to beneﬁt greatly from the targeting ability of the
liposomes although this aspect needs to be speciﬁcally
addressed in future experiments. Fig. 6c shows gamma camera
images at diﬀerent times after injection of 111In-(C18)2DOTA/
(C18)2L5-[7-14]BN containing aggregates. The images
conﬁrm the high uptake in liver and spleen and clearly show
accumulation in the receptor positive tumors. There is similar
contrast between the diﬀerent organs at the three time points,
indicating that the relative diﬀerences in concentration of the
compound in normal organs and in the tumor is maintained
throughout the 48 h observation period.
3. Conclusion
New supramolecular aggregates based on the combination of
two amphiphilic synthetic monomers have been prepared and
structurally characterized. Even if we have already explored
the basic concept to obtain peptide modiﬁed supramolecular
aggregates, as selective delivery systems, by combining
together two amphiphilic monomers, the systems here
reported are very innovative both for their chemical composition
and for their potential application. The presence of the cyclic
chelating agent, DOTA, with only three negative charges,
on the most abundant monomer, constrains the liposomal
structure of the aggregates. In fact, structural characterization
Fig. 6 Animal studies. (A) Blood time activity curve following
intravenous injection of 111In-(C18)2DOTA/(C18)2L5-[7-14]BN
aggregates (squares) and 111In-(C18)2DOTA/(C18)2L5-[7-14]scrBN
aggregates (circles). Error bars = SD. Blood clearance of radioactivity
is slow and similar for the two aggregates. (B) Organ biodistribution at
48 h after injection of 111In-(C18)2DOTA/(C18)2L5-[7-14]BN
aggregates (black bars) and 111In-(C18)2DOTA/(C18)2L5-[7-14]scrBN
aggregates (white bars). Error bars = SD. There is high liver
concentration of both aggregates. Uptake in other organs is similar
for the two compounds. Higher uptake is observed for
111In-(C18)2DOTA/(C18)2L5-[7-14]scrBN aggregates in the GRPR
positive tumors. (C) Gamma camera images (ventral view) at diﬀerent
times after injection of 111In-(C18)2DOTA/(C18)2L5-[7-14]scrBN
aggregates. Highest uptake is observed in liver although activity in
spleen as well as in the tumor located in the right ﬂank are clearly
visible over background. Relative concentration of radioactivity in the
diﬀerent organs does remains relatively constant over the 48 h
observation period.
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by SANS and DLS techniques indicates the tendency of the
DOTA amphiphilic monomer to form stable liposomes,
independent of the presence of 10% in peptide monomer in
the ﬁnal composition. The hydrodynamic radius and bilayer
thickness values are around 200 nm and 4 nm, respectively.
This structure is diﬀerent from that observed for similar
aggregates previously studied13 in which DTPAGlu
amphiphilic monomer is present, and highly polydisperse
aggregates (rod-like micelles, open bilayers and vesicles) were
found. This behavior could be explained on the basis of
the lower negative charge (3) of DOTA with respect to
DTPAGlu (5): a decrease of the electrostatic repulsion
between the headgroups favours the formation of large and
low curvature aggregates such as liposomes.31
The presence of [7-14] bombesin peptide allows the bombesin
receptors, such as the gastrin-releasing peptide receptor
(GRPR), to be targeted. These receptors have been found
overexpressed by tumor cell lines of several human tumors,
including prostate cancers, breast carcinomas, SCLSs and
non-SCLSs, renal cell carcinomas and ovarian tumors. In vitro
and in vivo results encourage new studies on the possibility to
use these systems as target selective delivery systems of drug
and/or imaging probes, in pathologies associated with high
expression of bombesin receptors. In fact, in vitro data show
speciﬁc binding of the 111In-(C18)2DOTA/(C18)2L5-[7-14]BN
containing aggregates in receptor expressing cells, while the
presence of a Peg3000 unit on the external liposomal surface
could hide the peptide and prevent the receptor binding.
In vivo experiments using 111In-(C18)2DOTA/(C18)2L5-[7-14]BN
show the expected biological behavior of aggregates of such
size and molecular composition and preliminarily conﬁrm
their ability to speciﬁcally target and concentrate in receptor
expressing xenografts. Further work will delineate to what
extent therapeutic eﬃcacy can be increased by such an
approach in the animal model currently presented.
4. Experimental
Protected Na-Fmoc-amino acid derivatives, coupling reagents
and Rink-amide p-methylbenzhydrylamine MBHA resin were
purchased from Calbiochem-Novabiochem (Laufelﬁngen,
Switzerland). The Fmoc-8-amino-3,6-dioxaoctanoic acid
(Fmoc-AdOO-OH) was purchased fromNeosystem (Strasbourg,
France). DOTA(OtBu)3-OH and Lys[DOTA(OtBu)3]-OH
derivative were purchased from Macrocycles (Dallas, TX
USA). a-(9-Fluorenylmethyloxycarbonyl) amino-o-carboxy
poly(ethylene glycol) (Fmoc-NH-Peg3000-COOH) was
purchased by Iris Biotech GmbH (Marktredwitz, Germany).
N,N-dioctadecylsuccinamic acid was synthesized according to
literature.32 [111In]Cl3 was purchased from Mallinckrodt Med.
(Petten, The Netherlands). All other chemicals were commercially
available by Sigma-Aldrich, Fluka (Buchs, Switzerland) or
LabScan (Stillorgan, Dublin, Ireland) and were used as
received unless otherwise stated. All solutions were prepared
by weight using doubly distilled water. The pH of all solutions
was kept constant at 7.4. Preparative HPLC was carried out
on a LC8 Shimadzu HPLC system (Shimadzu Corporation,
Kyoto, Japan) equipped with a UV lambda-Max Model
481 detector using a Phenomenex (Torrance, CA) C4
(300 A˚, 250  21.20 mm, 5 m) column eluted with an
H2O/0.1% TFA (A) and CH3CN/0.1% TFA (B) system from
20% to 95% over 25 min at a ﬂow rate of 20 mL min1.
1H and 13C NMR spectra were recorded using 400 spectrometer
Varian (Palo Alto, CA USA). LC-MS analyses were
performed by using Finnigan Surveyor MSQ single quadrupole
electrospray ionization (Finnigan/Thermo Electron Corporation
San Jose, CA). UV measurements were performed on a UV-vis
Jasco V-5505 spectrophotometer equipped with a Jasco
ETC-505T Peltier temperature controller with a 1 cm quartz
cuvette (Hellma).
4.1 Synthesis of (C18H37)2CONHLys-(DOTA)CONH2
((C18)2DOTA)
The monomer was synthesized on solid phase using
Rink-amide (MBHA) resin (0.85 mmol g1; 0.2 mmol, 0.235 g)
as polymeric support. After the swelling of the resin in 2 mL of
dimethylformamide (DMF) for 1 h, the Fmoc protecting
group was removed by adding a mixture of piperidine–DMF
30 : 70. The carboxylic group of Fmoc-Lys(Mtt)-OH (0.8 mmol,
0.500 g) was activated by 1 equiv. of benzotriazol-1-yl-oxy-
tris(pyrrolidino)phosphonium (PyBop), 1-hydroxybenzotriazole
(HOBt) and 2 equiv. of N,N-diisopropylethylamine (DIPEA)
in DMF. The solution was added to the resin and the slurry
suspension was stirred for 1 h. The coupling of the lysine
residue was performed twice and after ﬁltration, the coupling
was checked by the Kaiser colorimetric test. The solution was
ﬁltered and the resin washed with three portions of DMF and
three portions of dichloromethane (DCM). The 4-methyl-trityl
protecting group (Mtt) was removed by treatment of the resin
with DCM–tri-isopropylsylane (TIS)–triﬂuoroacetic acid
(TFA) (94 : 5 : 1) mixture stirring for 5 min. This procedure
was repeated several times until the solution became colourless.
The resin was washed three times with DCM and three times
with DMF. DOTA(OtBu)3-OH (2 equiv., 0.252 g) was
dissolved in DMF. Two equivalents of O-(7-azabenzotriazol-
1-yl)-1,1,3,3-tetramethyluronium (HATU) and 4 equiv. of
DIPEA were used to perform the coupling and the reaction
was monitored by Kaiser test. Then, after the removal of
N-terminal Fmoc protecting group in previous described
condition, N,N-dioctadecylsuccinamic acid (0.4 mmol, 0.249 g)
was condensed twice for 1 h in the DMF–DCM (50 : 50)
mixture. The lipophilic moiety was activated in situ by the
standard HOBt–PyBop–DIPEA procedure. The cleavage
from the resin and deprotection of the tBu protecting groups
were obtained stirring for 2 h in TFA containing 2.5% (v/v)
water and 2.0% (v/v) TIS as scavengers at room temperature.
The crude product was slowly precipitated at 0 1C by adding
water drop-wise. The solid was washed several times with
small portions of cold water, and lyophilized. The white solid
was recrystalized from MeOH–H2O and recovered in high
yield (>85%). The product was identiﬁed by mass spectra
(electrospray ionization ESI) and NMR spectroscopy.
(C18)2DOTA: MS (ESI
+): m/z (%): 1134 (100) [M-H+]
1H NMR (CDCl3–CD3OD 50 : 50) chemical shifts d (CHCl3 as
internal standard 7.26) = 4.1 (m, 1H, CH Lys a), 3.6 (m, 2H,
R2NCH2CONH), 3.1 (m, 6H, R2N–CH2COOH), 3.0 2H,
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CH2 Lys e), 3.1 (m, 16 R2N–CH2CH2NR2) 2.4–2.1 (m, 4H,
COCH2CH2CO), 1.7 (m, 2H, CH2 Lys b), 1.4 (m, 2H, CH2
Lys d), 1.3 (m, 2H, CH2 Lys g), 1.1 (m, 4H, RCH2CH2N),
1.0 (m, 60 CH2 aliphatic), 0.70 (t, 6H, CH3).
13C NMR (CDCl3–CD3OD 50 : 50) chemical shifts d
(CDCl3 as internal standard 77.00) = 174.0 (3, COOH),
172.8, 172.6, 172.1, 163.0 (4 CONH), 54.5 (CH Lys a), 53.2
(CH2COOH), 51.50 (NCH2CH2N), 49.7 (CH3(CH2)16CH2N),
46.4 (CH3(CH2)15CH2CH2N), 38.0 (CH2 Lys e), 36.0
(CH2 Lys b), 32.0 (NCOCH2CH2CONH), 31.8 (CH2 Lys g),
29.60–27.0 (CH3CH2CH2(CH2)13CH2CH2N), 22.57 (CH3CH2-
CH2(CH2)15), 22.2 (CH2 Lys d), 13.73 (CH3CH2(CH2)16).
4.2 Peptide conjugate synthesis
Peptide syntheses were carried out in solid-phase under
standard Fmoc strategy, by using 433A Applied Biosystems
automatic synthesizer. Rink-amideMBHA resin (0.78 mmol g1,
0.5 mmol scale, 0.640 g) was used. The elongations of the
[7-14]BN and scrBN peptides were achieved by sequential
addition of Fmoc-AA-OH with PyBOP–HOBt–DIPEA
(1 : 1 : 2) as coupling reagents, in DMF in pre-activation mode.
The mixture was stirred for 1 h and after ﬁltration. All
couplings were performed twice for 1 h, by using an excess
of 4 equivalents for the single amino acid derivative. Fmoc
deprotections were obtained by 30% solution of piperidine in
DMF. Fmoc-AdOO-OH and Fmoc-NH-Peg3000-COOH linkers
were coupled manually in DMF by using an excess of 2
equivalents. N,N-dioctadecylsuccinamic acid coupling was
performed as previously described for (C18)2DOTA synthesis.
DOTA-bAla-[7-14]BN and DOTA-bAla-scrBN: Rt =
19.1 min; MW = 1525 amu; [M + H+] = 1526.0 amu.
(C18)2L5-[7-14]BN and (C18)2L5-scrBN: Rt = 22.50 min;
MW = 2264 amu; [M + 2H+]/2 = 1133.0 amu.
(C18)2Peg3000-[7-14]BN and (C18)2Peg3000-scrBN: Rt =
21.9 min; MW = 4544 amu; [M + 3H+]/3 = 1515.7 amu,
[M+2H++Na+]/3 = 1523.0 amu.
4.3 Aggregates preparation
All solutions were prepared by weight, buﬀering the samples at
pH 7.4 by using 0.1 M phosphate buﬀer. pH was controlled by
using pH meter MeterLab PHM 220. In most cases the
samples to be measured were prepared from stock solutions.
Pure aggregates of (C18)2DOTA and mixed aggregates
of (C18)2DOTA/(C18)2L5-[7-14]BN and (C18)2DOTA/
(C18)2Peg3000-[7-14]BN (or aggregates containing their
corresponding scrBN peptide) were prepared by dissolving
the amphiphiles, in a small amount of a methanol–chloroform
(50 : 50) mixture, and subsequently evaporating the solvent by
slowly rotating the tube containing the solution under a
stream of nitrogen. In this way a thin ﬁlm of amphiphile was
obtained. Then the ﬁlm was hydrated by addition of 0.1 M
phosphate buﬀer (pH= 7.4) solution in the vial and sonicated
for 30 min. All mixed aggregates were prepared at
90 : 10 molar ratios between monomer containing the chelating
agent and the monomer containing the [7-14]BN or scrBN
peptide. Concentrations of solutions containing peptide
surfactant were determined by absorbance measurements. A
molar absorptivity (e280) of 5630 M
1 cm1 was used taking
into account the contribution from tryptophan present in the
primary of the bombesin.33,34 In all solutions used for SANS
investigations, H2O has been replaced by D2O in order to
minimize the incoherent contribution to the total scattering
cross section.
4.4 Small angle neutron scattering (SANS)
Small angle neutron scattering measurements were performed
at 25 1C with the KWS2 instrument located at the Heinz Meier
Leibtnitz Source, Garching Forschungszentrum (Germany).
Neutrons with a wavelength spread Dl/l r 0.2 were used.
A two-dimensional array detector at three diﬀerent wavelengths
(W)/collimation(C)/sample-to-detector(D) distance combinations
(W7 A˚C8mD2m, W7 A˚C8mD8m and W19 A˚C8mD8m), measured
neutrons scattered from the samples. These conﬁgurations
allowed data collection in a range of the scattering vector
modulus q= 4p/lsin(y/2) between 0.0019 A˚1 and 0.179 A˚1,
where y is the scattering angle. The investigated systems were
contained in a closed quartz cell, in order to prevent solvent
evaporation and measurements taken for a period so as to
allow B2 million counts. The obtained raw data were then
corrected for background and empty cell scattering. Detector
eﬃciency corrections, radial average and transformation to
absolute scattering cross sections dS/dO were made with a
secondary plexiglass standard.35,36
4.5 Dynamic light scattering (DLS)
The light scattering setup was composed by a Photocor
compact goniometer, a SMD 6000 Laser Quantum 50 mW
light source operating at 5325 A˚ and a PMT and correlator
acquired from www.correlator.com.
In DLS, the intensity autocorrelation function g(2)(t) is
measured and related to the electric ﬁeld autocorrelation
g(1)(t) by the Siegert relation. The parameter g(1)(t) can be
written as the Laplace transform of the distribution of the
relaxation rate G. Such Laplace transformations were
performed using algorithm incorporated in Precision Deconvolve
software. From the relaxation rates, the translational diﬀusion






where q = 4pn0/lsin(y/2) is the modulus of the scattering
vector, n0 is the refractive index of the solution, l is the
incident wavelength and y represents the scattering angle.
Thus D is obtained from the limit slope of G as a function
of q2, where G is measured at diﬀerent scattering angles. All
the measurements were performed at (25.00  0.05) 1C by
using a thermostat bath.
4.6 Preparation of the radiotracers
The DOTA-bAla-[7-14]BN and DOTA-bAla-scrBN radio-
peptides were prepared according to Wild et al.38 Brieﬂy, 10 mg
of peptide in 250 mL of sodium acetate buﬀer (0.4 mol L1,
pH 5.0) were incubated with 111InCl3 (3 to 5 mCi) for 30 min at
95 1C and then excess of natInCl3  5H2O was added to aﬀord
structurally characterized homogenous ligands. Radiolabeling
of the aggregates was performed at a ﬁnal concentration of
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2  104 M. Trace amounts of 111InCl3 (100 mCi) were
added to 1 mL of the aggregates and sodium acetate buﬀer
(0.4 mol L1, pH 5.0) was added to reach a ﬁnal volume of
2 mL. The mixture was incubated for 30 min at 90 1C.
Conﬁrmation of incorporation of the label into the aggregates
was obtained by gel ﬁltration on Sephadex G-50 pre packed
columns (Pharmacia Biotech).
4.7 In vitro studies
PC-3 cells were seeded into 6-well plates wherein they
remained overnight (0.8–1.0  106 cells per well). On the day
of the experiment the medium was removed, the cells were
washed twice with fresh medium (DMEM with 1% fetal
bovine serum, pH 7.4) and incubated for 1 h at 37 1C.
Internalization experiments of the 111In-labeled peptides were
performed as indicated in the literature.39 Approximately
0.08 mCi of 111/natIn-labeled peptide (0.25 pmol) were added
to the medium and the cells were incubated (in triplicates) for
0.5, 1, 2 and 4 h at 37 1C, 5% CO2. A 1000 fold excess of
[Tyr4]-BN was used to determine non-speciﬁc internalization.
At each time point the internalization was stopped by removing
the medium followed by washing the cells with ice-cold solutions
of phosphate-buﬀered saline (PBS, pH 7.4). Cells were then
treated for 5 min (twice) with glycine buﬀer (0.05 mol L1
glycine solution, pH adjusted to 2.8 with 1 mol L1 HCl) to
distinguish between cell surface-bound (acid releasable) and
internalized (acid resistant) radioligand. Finally, the cells were
detached from the plates by incubating with 1 mol L1 NaOH
for 10 min at 37 1C. An amount of 0.5 mCi (100 mL) per well
of 111/natIn-labeled aggregates to a ﬁnal concentration of
2  104 M were added to the medium and the cells were
incubated (in triplicates) for 0.5, 1, 2 and 4 h at 37 1C, 5%
CO2. Afterwards, the binding buﬀer was aspirated and the
cells were washed twice with ice-cold phosphate-buﬀered
saline (PBS, pH 7.4); this represented the unbound fraction.
The cells were then collected with 1 N NaOH; this
corresponded to the bound fraction. The calculations of the
in vitro experiments were done by measuring the radioactivity
of each collected fraction in a g-counter (Cobra II; Packard
Instrument Co.) related to the standards.
4.8 In vivo studies
Animal experiments were carried out on 6 week old female
CD1 nude mice (Charles River Italia). Mice bearing xenografts
of PC-3 cells were generated as previously described.13 Brieﬂy,
100 mL of the cell suspensions at a density of 2–3 107 mL1 in
PBS were injected in the ﬂank of mice (weight 17–23 g).
Biodistribution and imaging experiments were performed
two weeks after implanting cells (tumor sizes were between
0.5 and 1 g). Procedures involving animals and their care were
in conformity with institutional guidelines that comply with
national and international laws and policies. Approximately
100 mCi of 111In-labeled aggregate preparation ((C18)2DOTA/
(C18)2L5-[7-14]BN and the corresponding aggregates in which
the BN peptide is replaced by the scrambled peptide) were
injected into the lateral tail vein of each mouse (n = 5).
Imaging was performed at diﬀerent times after injection,
following administration of an intraperitoneal anesthetic on
a clinical gamma camera equipped with a medium energy
collimator. Venous orbital sinus samples were also collected at
diﬀerent times to obtain blood time activity curves. The
animals were killed 48 h after injection, imaged and sub-
sequently dissected in order to quantitatively determine organ
concentrations of radioactivity by weighing and counting each
dissected organ. Dilutions of the injected compound were
simultaneously counted for accurate determination of the
injected dose. The relative amount of radioactivity in the
organs was calculated and expressed as a percentage of
the injected dose/gram tissue (%ID/g) normalized to a
20 g mouse.
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